{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-012791","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2025-05-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.211747+00:00","generated_at":"2026-05-20T05:41:20.492350+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cocrystal Pharma Reports CC-42344 Shows 1,000-fold Greater Potency Than Tamiflu Against H5N1 Avian Flu","bullets":["CC-42344 exhibited EC50 of 0.003 µM against the 2024 Texas H5N1 strain, ~1,000-fold more potent than Tamiflu (EC50 2.69 µM).","The PB2 inhibitor targets a highly conserved active site and has shown favorable safety in a Phase 1 study.","H5N1 has spread in U.S. dairy cattle since March 2024, with rare human cases and low population immunity according to CDC.","Cocrystal plans further clinical evaluation of CC-42344 for pandemic and seasonal influenza treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-012791","json":"https://secwatch.observer/filing/0001641172-25-012791.json","markdown":"https://secwatch.observer/filing/0001641172-25-012791.md","text":"https://secwatch.observer/filing/0001641172-25-012791.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000164117225012791/0001641172-25-012791-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000164117225012791/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-20T05:41:20.492350+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}